Early Sodium-Glucose Cotransporter-2 Inhibitor Use After Acute Kidney Injury in Type 2 Diabetes.
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors improve kidney and cardiovascular outcomes in type 2 diabetes, chronic kidney disease, and heart failure, but optimal initiation timing after dialysis-requiring acute kidney injury (AKI-D) is uncertain. To compare outcomes associated with SGLT-2 inhibitor prescription within 30 days vs 31 to 90 days after discharge among adults with type 2 diabetes recovering from AKI-D.
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors improve kidney and cardiovascular outcomes in type 2 diabetes, chronic kidney disease, and heart failure, but optimal initiation timing after dialysis-requiring acute kidney injury (AKI-D) is uncertain. To compare outcomes associated with SGLT-2 inhibitor prescription within 30 days vs 31 to 90 days after discharge among adults with type 2 diabetes recovering from AKI-D.
What the study was
- Study design
- Randomized Controlled Trial (inferred)
- Category
- Diagnostics
- Maturity
- Potentially Practice-Changing
- Journal
- JAMA Netw Open
Why it surfaced
Matched watchlist topic 'Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk'. Study design: Randomized Controlled Trial (inferred). Score: 8/10 (N:1, R:3, D:2, P:2).
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.